← All trials
NCT06052813
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2023
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2027
- First posted
- Sep 25, 2023
- Last posted
- Sep 25, 2023
- Enrollment
- 90
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ServierLead sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.Lead sponsor
- China Medical UniversityOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Nanchang UniversityOverall official - principal investigator
- Soochow UniversityOverall official - principal investigator
- Tongji UniversityOverall official - principal investigator
- Nanchang UniversityOfficial
- China Medical UniversityOfficial
- Tongji UniversityOfficial
- Henan Medical UniversityOfficial
- Southern Medical UniversityOfficial
- Chinese Academy of Medical SciencesOfficial
- Soochow UniversityOfficial
- Zhejiang UniversityOfficial
- Zhejiang UniversityOfficial
- Qingdao UniversityOfficial
- Sichuan UniversityOfficial
- Hacettepe UniversityOfficial
- LanZhou UniversityOfficial
- Huazhong University of Science and TechnologyOfficial
- Peking UniversityOfficial
- Anhui Medical UniversityOfficial
- Wenzhou Medical UniversityOfficial
- Jiao Tong UniversityOfficial
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.